Tag: Gmg treatment

According to clinical trial data, the most common adverse reactions reported in at least 10% of patients treated with nipocalimab breakthrough therapy designation BTD were respiratory tract infection, peripheral edema, and muscle spasms. This FcRn inhibitor is under evaluation for several autoimmune and alloimmune conditions, making a review of its safety profile essential.

In 2025, the U.S. Food and Drug Administration (FDA) approved a significant new infusion for generalized myasthenia gravis (gMG), prompting many to ask what is the new pill for myasthenia gravis. While no new oral pill has been recently approved, recent advancements have focused on more targeted therapies delivered via injection or infusion that offer new hope for managing symptoms.

In October 2023, the U.S. Food and Drug Administration (FDA) approved zilucoplan (brand name ZILBRYSQ®), which became the first self-administered, once-daily injection for myasthenia gravis (MG). This new treatment option offers a convenient and flexible alternative for eligible adults with generalized MG who are anti-acetylcholine receptor (AChR) antibody-positive.